ARAnthony Rusk

Anthony Rusk

*This is an algorithmically generated author record based on publicly available information.

Anthony Rusk has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multi-site feasibility study for personalized medicine in canines with Osteosarcoma

    by Noel R Monks, David M Cherba, Steven G Kamerling, Heather Simpson, Anthony W Rusk, Derrick Carter, Emily Eugster, Marie Mooney, Robert Sigler, Matthew Steensma, et al.

    A successful therapeutic strategy, specifically tailored to the molecular constitution of an individual and their disease, is an ambitious objective of modern medicine. In this report, we highlight a feasibility study in canine osteosarcoma focused on refining the infrastructure and processes required for prospective clinical trials using a series of gene expression-based Personalized Medicine (PMed) algorithms to predict suitable therapies within 5 days of sample receipt. Tumor tissue samples were collected immediately following limb amputation and shipped overnight from veterinary practices. Upon receipt (day 1), RNA was extracted from snap-frozen tissue, with an adjacent H&E section for pathological diagnosis. Samples passing RNA and pathology QC were shipped to a CLIA-certified laboratory for genomic profiling. After mapping of canine probe sets to human genes and normalization against a (normal) reference set, gene level Z-scores were submitted to the PMed algorithms. The resulting PMed report was immediately forwarded to the veterinarians. Upon receipt and review of the PMed report, feedback from the practicing veterinarians was captured. 20 subjects were enrolled over a 5 month period. Tissue from 13 subjects passed both histological and RNA QC and were submitted for genomic analysis and subsequent PMed analysis and report generation. 11 of the 13 samples for which PMed reports were produced were communicated to the veterinarian within the target 5 business days. Of the 7 samples that failed QC, 4 were due to poor RNA quality, whereas 2 were failed following pathological review. Comments from the practicing veterinarians were generally positive and constructive, highlighting a number of areas for improvement, including enhanced education regarding PMed report interpretation, drug availability, affordable pricing and suitable canine dosing. This feasibility trial demonstrated that with the appropriate infrastructure and processes it is possible to perform an in-depth molecular analysis of a patient’s tumor in support of real time therapeutic decision making within 5 days of sample receipt. A number of areas for improvement have been identified that should reduce the level of sample attrition and support clinical decision making.


  • Open Access

    Prospective Study of Thrombospondin-1 Mimetic Peptides, ABT-510 and ABT-898, in Dogs with Soft Tissue Sarcoma

    by A.I. Sahora, A.W. Rusk, J. Henkin, E.M. McKeegan, Y. Shi, C. Khanna

    Background Exposure to anti‐angiogenic thrombospondin‐1 (TSP‐1) mimetic peptides (MPs) has resulted in sporadic anti‐tumor activity in humans and dogs. Hypothesis Novel TSP‐1 MPs formulations will be safe, tolerated, and clinically active in soft tissue sarcoma (STS) in dogs. Animals Sixty‐two client‐owned dogs with measurable STS were enrolled, excluding hemangiosarcoma. Methods A prospective, single agent, multicenter, open‐label study assessing ABT‐510 bolus, ABT‐898 bolus, or ABT‐898 depot formulations of TSP‐1 in dogs. Endpoints included tolerability, antitumor activity, and the assessment of ability of clinical covariates and circulating endothelial cells (CEC) concentration to predict tumor response. Results Two non‐dose‐limiting toxicoses possibly attributed to treatment were observed (keratitis and osteoarthritis). Antitumor activity (10/44 = 23% responses) was observed in study subjects who received treatment for >28 days (n = 44) including both partial (7) and minimal responses (3). Responses were disproportionately seen in dogs receiving ABT‐898 formulations (9/28 = 32%) versus those receiving ABT‐510 (1/16 = 6%; P < .045). Disease stabilization for >84 days was also documented (8/44 = 18%). Slow rates of tumor progression before study entry correlated with anti‐tumor activity in treated dogs, whereas no significant association was found between changes in total CEC concentration and tumor response (P = .28) or time to progression (P = .42). Conclusions and Clinical Importance Safely achieved antitumor activity was documented with TSP‐1 MPs in dogs with STS. The most notable activity was achieved with the ABT‐898 formulations.


  • Open Access

    Cooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma

    by Anthony Rusk, Elizabeth Cozzi, Marty Stebbins, David Vail, Joanne Graham, Victor Valli, Jack Henkin, Rick Sharpee, Chand Khanna

    Purpose: Thrombospondin-I (TSP-I) is a natural antiangiogenic protein that enhances apoptosis of activated endothelial cells. A modified nonapeptide from TSP-I, ABT-526, has been found to be active in mouse cancer models and in dogs with naturally occurring cancers. To further assist in the development of ABT-526, we report herein on its evaluation in combination with cytotoxic chemotherapy in pet dogs with relapsed non-Hodgkin's lymphoma (NHL).


  • Open Access

    Preclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs with Naturally Occurring Cancers

    by Anthony Rusk, Evelyn McKeegan, Fortuna Haviv, Sandra Majest, Jack Henkin, Chand Khanna

    Purpose: The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy. ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice. To guide the clinical development of these drugs, translational studies in dogs with naturally occurring cancers were initiated.